A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

NCT05446688 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: 6MW3211

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.